Enanta Pharmaceuticals Company Profile (NASDAQ:ENTA)

About Enanta Pharmaceuticals

Enanta Pharmaceuticals logoEnanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV). It has discovered novel protease inhibitors that are members of the direct-acting-antiviral (DAA) inhibitor classes designed for use against the hepatitis C virus (HCV). These protease inhibitors, developed through its collaboration with AbbVie Inc. (AbbVie), include paritaprevir and glecaprevir (ABT-493). Its product candidates also include EDP-305, which is a farnesoid X receptor (FXR) agonist product candidate for NASH and PBC, and EDP-938, which is a clinical candidate for RSV.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ENTA
  • CUSIP:
Key Metrics:
  • Previous Close: $27.72
  • 50 Day Moving Average: $32.00
  • 200 Day Moving Average: $28.32
  • 52-Week Range: $19,041,000.00 - $20.79
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $527.82M
  • Outstanding Shares: 19,041,000
  • Beta: 0.81
Profitability:
  • Net Margins: -18.92%
  • Return on Equity: -3.54%
  • Return on Assets: -3.38%
Debt:
  • Current Ratio: 34.85%
  • Quick Ratio: 34.85%
Additional Links:
Companies Related to Enanta Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Enanta Pharmaceuticals (NASDAQ:ENTA) (?)
Ratings Breakdown: 1 Hold Rating, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $26.50 (4.40% downside)

Analysts' Ratings History for Enanta Pharmaceuticals (NASDAQ:ENTA)
Show:
DateFirmActionRatingPrice TargetDetails
11/22/2016Robert W. BairdReiterated RatingOutperform$22.00 -> $27.00View Rating Details
8/9/2016J P Morgan Chase & CoSet Price TargetBuy$31.00 -> $26.00View Rating Details
4/28/2016JMP SecuritiesDowngradeOutperform -> Market PerformView Rating Details
2/9/2016Barclays PLCBoost Price TargetUnderweight$16.00 -> $18.00View Rating Details
5/8/2015Leerink SwannLower Price TargetOutperform$42.00 -> $41.00View Rating Details
4/6/2015Deutsche Bank AGInitiated CoverageBuy$42.00 -> $42.00View Rating Details
(Data available from 2/27/2015 forward)

Earnings

Earnings History for Enanta Pharmaceuticals (NASDAQ:ENTA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2017        
2/8/2017Q117($0.18)($0.26)$12.70 million$11.90 millionViewListenView Earnings Details
11/21/2016Q416($0.14)($0.09)$13.56 million$12.80 millionViewListenView Earnings Details
8/8/2016Q216($0.09)($0.06)$13.07 million$14.00 millionViewListenView Earnings Details
5/9/2016Q2$0.10($0.09)$16.80 million$13.00 millionViewListenView Earnings Details
2/8/2016Q116$1.13$1.36$47.32 million$48.40 millionViewListenView Earnings Details
11/23/2015Q415$0.15$0.29$16.44 million$14.40 millionViewListenView Earnings Details
8/6/2015Q315$0.19$0.13$16.18 million$11.60 millionViewListenView Earnings Details
5/7/2015Q215$1.80$1.49$63.40 million$57.40 millionViewListenView Earnings Details
2/5/2015Q115$3.82$2.18$86.62 million$77.50 millionViewN/AView Earnings Details
11/24/2014Q414($0.33)($0.27)$3.81 million$2.60 millionViewListenView Earnings Details
8/11/2014Q314$1.67$2.61$40.83 million$42.10 millionViewN/AView Earnings Details
5/12/2014Q2$0.69($0.28)$1.20 million$2.20 millionViewListenView Earnings Details
2/13/2014Q114($0.15)($0.30)$1.41 million$0.89 millionViewN/AView Earnings Details
11/25/2013Q4($0.29)($0.25)$1.00 million$1.30 millionViewListenView Earnings Details
8/12/2013Q213($0.34)($0.23)$0.73 million$1.60 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Enanta Pharmaceuticals (NASDAQ:ENTA)
Current Year EPS Consensus Estimate: $0.00 EPS
Next Year EPS Consensus Estimate: $-0.24 EPS

Dividends

Dividend History for Enanta Pharmaceuticals (NASDAQ:ENTA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Enanta Pharmaceuticals (NASDAQ:ENTA)
Insider Ownership Percentage: 9.28%
Institutional Ownership Percentage: 71.61%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/4/2017Yat Sun OrInsiderSell13,921$35.09$488,487.89View SEC Filing  
11/29/2016Yat Sun OrInsiderSell13,921$31.44$437,676.24View SEC Filing  
5/11/2016Nathaniel S GardinerVPBuy500$24.45$12,225.00View SEC Filing  
2/12/2016Terry VanceDirectorBuy2,000$27.04$54,080.00View SEC Filing  
11/24/2015Paul J. MellettCFOSell6,000$30.15$180,900.00View SEC Filing  
10/15/2015Paul J MellettCFOSell7,500$40.10$300,750.00View SEC Filing  
9/8/2015Paul J. MellettCFOSell7,500$39.55$296,625.00View SEC Filing  
7/13/2015Paul J MellettCFOSell7,500$46.29$347,175.00View SEC Filing  
7/13/2015Yat Sun OrInsiderSell3,750$46.29$173,587.50View SEC Filing  
6/11/2015Paul J MellettCFOSell7,500$42.51$318,825.00View SEC Filing  
6/11/2015Yat Sun OrInsiderSell3,750$42.47$159,262.50View SEC Filing  
6/5/2015Yat Sun OrInsiderSell10,750$42.02$451,715.00View SEC Filing  
5/19/2015Paul J MellettCFOSell24,000$40.13$963,120.00View SEC Filing  
5/11/2015Yat Sun OrInsiderSell8,000$36.13$289,040.00View SEC Filing  
3/9/2015Jay R LulyCEOSell15,000$33.37$500,550.00View SEC Filing  
2/20/2015Jay R LulyCEOSell15,000$35.35$530,250.00View SEC Filing  
2/19/2015Stephen Jr. BuckleyDirectorBuy1,000$34.00$34,000.00View SEC Filing  
2/17/2015Nathaniel S GardinerVPBuy1,400$33.23$46,522.00View SEC Filing  
1/16/2015Paul J MellettCFOSell4,500$49.45$222,525.00View SEC Filing  
1/5/2015Jay R LulyCEOSell15,000$50.43$756,450.00View SEC Filing  
12/1/2014Jay R LulyCEOSell15,000$45.39$680,850.00View SEC Filing  
11/3/2014Jay R LulyCEOSell15,000$42.52$637,800.00View SEC Filing  
9/15/2014Paul J MellettCFOSell10,000$39.83$398,300.00View SEC Filing  
8/14/2014Paul J MellettCFOSell10,000$39.13$391,300.00View SEC Filing  
8/14/2014Stephen Jr. BuckleyDirectorBuy1,000$38.95$38,950.00View SEC Filing  
7/14/2014Paul J MellettCFOSell20,000$39.88$797,600.00View SEC Filing  
5/1/2014Yat Sun OrInsiderSell5,000$36.98$184,900.00View SEC Filing  
4/1/2014Jay LulyCEOSell15,000$39.17$587,550.00View SEC Filing  
4/1/2014Yat Sun OrInsiderSell10,000$39.16$391,600.00View SEC Filing  
3/24/2014Yat Sun OrInsiderSell10,000$39.34$393,400.00View SEC Filing  
3/4/2014V Life Science Ventures Gm Tvmmajor shareholderSell439,334$38.82$17,054,945.88View SEC Filing  
2/26/2014V Life Science Ventures Gm Tvmmajor shareholderSell230,190$39.15$9,011,938.50View SEC Filing  
2/24/2014V Life Science Ventures Gm Tvmmajor shareholderSell60,477$39.57$2,393,074.89View SEC Filing  
2/14/2014Jay LulyCEOSell5,800$38.10$220,980.00View SEC Filing  
1/2/2014Jay R LulyCEOSell5,800$28.05$162,690.00View SEC Filing  
12/6/2013Marc E GoldbergDirectorSell6,861$27.93$191,627.73View SEC Filing  
10/14/2013Saints Capital Granite, L.P.Major ShareholderSell32,301$19.84$640,851.84View SEC Filing  
10/10/2013Saints Capital Granite, L.P.Major ShareholderSell36,207$21.71$786,053.97View SEC Filing  
10/3/2013Saints Capital Granite, L.P.Major ShareholderSell12,300$23.39$287,697.00View SEC Filing  
3/26/2013Helmut SchuhslerDirectorBuy132,949$14.00$1,861,286.00View SEC Filing  
3/26/2013Saints Capital Granite, L.P.Major ShareholderBuy66,474$14.00$930,636.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Enanta Pharmaceuticals (NASDAQ:ENTA)
DateHeadline
News IconFusion Pharmaceuticals Company Profile (NASDAQ:ENTA)
www.bioportfolio.com - February 23 at 10:01 PM
News IconEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Projected to Achieve EPS Of $-0.38 - Stock Observer (NASDAQ:ENTA)
www.thestockobserver.com - February 23 at 5:00 PM
biz.yahoo.com logoENANTA PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders (NASDAQ:ENTA)
biz.yahoo.com - February 22 at 8:04 AM
News IconAre Analysts Optimistic About Where Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) is Heading? - Winfield Review (NASDAQ:ENTA)
winfieldreview.com - February 18 at 4:40 PM
News IconStock Numbers: Checking on Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Sherwood Daily (NASDAQ:ENTA)
sherwooddaily.com - February 16 at 4:28 PM
capitalcube.com logoEnanta Pharmaceuticals, Inc. :ENTA-US: Earnings Analysis: Q1, 2017 By the Numbers : February 15, 2017 (NASDAQ:ENTA)
www.capitalcube.com - February 16 at 4:28 PM
finance.yahoo.com logoENANTA PHARMACEUTICALS INC Financials (NASDAQ:ENTA)
finance.yahoo.com - February 16 at 4:28 PM
biz.yahoo.com logoENANTA PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report (NASDAQ:ENTA)
biz.yahoo.com - February 9 at 5:35 PM
biz.yahoo.com logoQ1 2017 Enanta Pharmaceuticals Inc Earnings Release - After Market Close (NASDAQ:ENTA)
us.rd.yahoo.com - February 8 at 5:30 PM
us.rd.yahoo.com logoEnanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2016 (NASDAQ:ENTA)
us.rd.yahoo.com - February 8 at 5:30 PM
biz.yahoo.com logoENANTA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an (NASDAQ:ENTA)
us.rd.yahoo.com - February 8 at 5:30 PM
biz.yahoo.com logoEnanta Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today (NASDAQ:ENTA)
us.rd.yahoo.com - February 8 at 5:30 PM
sg.finance.yahoo.com logoEnanta Pharmaceuticals reports 1Q loss (NASDAQ:ENTA)
sg.finance.yahoo.com - February 8 at 5:30 PM
finance.yahoo.com logoEnanta Pharmaceuticals to Present at Two Upcoming Investor Conferences (NASDAQ:ENTA)
finance.yahoo.com - February 6 at 5:02 PM
News IconU.S. FDA Grants Priority Review to AbbVie’s Investigational HCV Regimen of Glecaprevir/Pibrentasvir (G/P) (NASDAQ:ENTA)
hepatitiscnewdrugs.blogspot.com - February 2 at 5:29 PM
businesswire.com logoEnanta Announces U.S. FDA Grants Priority Review to AbbVie’s Investigational HCV Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of Chronic Hepatitis C in All ... (NASDAQ:ENTA)
www.businesswire.com - February 2 at 5:29 PM
tmcnet.com logoEnanta Announces U.S. FDA Grants Priority Review … (NASDAQ:ENTA)
www.tmcnet.com - February 2 at 5:29 PM
us.rd.yahoo.com logoEnanta Announces U.S. FDA Grants Priority Review to AbbVie’s Investigational HCV Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6) (NASDAQ:ENTA)
us.rd.yahoo.com - February 2 at 5:29 PM
News IconTechnical Update on Shares of Enanta Pharmaceuticals Inc. (ENTA) - Market Point (NASDAQ:ENTA)
mtptnews.com - January 31 at 10:39 PM
News IconTechnical Level Spotcheck on Shares of Enanta Pharmaceuticals Inc. (ENTA) - Rives Journal (NASDAQ:ENTA)
rivesjournal.com - January 30 at 3:31 PM
News IconInvestor Notebook: Focusing in on Shares of Enanta Pharmaceuticals Inc. (ENTA) - Market Point (NASDAQ:ENTA)
mtptnews.com - January 27 at 11:41 PM
News IconEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Stock ABR At 2.33 - Stock Observer (NASDAQ:ENTA)
www.thestockobserver.com - January 27 at 11:41 PM
News IconEarnings in Full Force, Analysts Take Aim at Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Wall Street Beacon (NASDAQ:ENTA)
wsbeacon.com - January 26 at 6:20 PM
News IconWhat are the Levels Showing for Shares of Enanta Pharmaceuticals Inc. (ENTA) - Market Point (NASDAQ:ENTA)
mtptnews.com - January 25 at 3:44 AM
businesswire.com logoEnanta Announces EMA Grants Accelerated Assessment, Validates Marketing Authorization Application for AbbVie’s Investigational HCV Regimen of Glecaprevir/Pibrentasvir (G/P ... (NASDAQ:ENTA)
www.businesswire.com - January 24 at 10:42 PM
benzinga.com logoEnanta Announces EMA Grants Accelerated... (NASDAQ:ENTA)
www.benzinga.com - January 24 at 5:40 PM
tmcnet.com logoEnanta Announces EMA Grants Accelerated Assessment, Validates Marketing … (NASDAQ:ENTA)
www.tmcnet.com - January 24 at 5:40 PM
finance.yahoo.com logoEuropean Medicines Agency Grants Accelerated Assessment, Validates Marketing Authorization Application for AbbVie's Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of Chronic Hepatitis C in All Major Genotypes (G (NASDAQ:ENTA)
finance.yahoo.com - January 24 at 5:40 PM
finance.yahoo.com logoEnanta Announces EMA Grants Accelerated Assessment, Validates Marketing Authorization Application for AbbVie’s Investigational HCV Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of All Major Genotypes (GT1-6) of Chronic Hepatit (NASDAQ:ENTA)
finance.yahoo.com - January 24 at 5:40 PM
capitalcube.com logoEnanta Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ENTA) : January 24, 2017 (NASDAQ:ENTA)
www.capitalcube.com - January 24 at 5:39 PM
tmcnet.com logoEnanta Pharmaceuticals to Host Conference Call on February … (NASDAQ:ENTA)
www.tmcnet.com - January 23 at 5:22 PM
capitalcube.com logoEnanta Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ENTA-US : January 23, 2017 (NASDAQ:ENTA)
www.capitalcube.com - January 23 at 9:22 AM
finance.yahoo.com logoEnanta Pharmaceuticals to Host Conference Call on February 8 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal First Quarter Ended December 31, 2016 (NASDAQ:ENTA)
finance.yahoo.com - January 23 at 9:22 AM
News IconWall Street Holds Inauguration Gains, How Did This Stock Fare: Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Wall Street Beacon (NASDAQ:ENTA)
wsbeacon.com - January 21 at 10:02 PM
News IconWhat are Research Firms Saying About Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)? - Aiken Advocate (NASDAQ:ENTA)
aikenadvocate.com - January 20 at 4:26 AM
News IconTrading Focus: Eye on Shares of Enanta Pharmaceuticals Inc. (ENTA) - Sherwood Daily (NASDAQ:ENTA)
sherwooddaily.com - January 17 at 5:25 AM
News IconWill The Needle Move For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:ENTA)
wsbeacon.com - January 13 at 3:56 PM
gurufocus.com logoEntana Pharmaceuticals Releases Study Results of Hepatitis Treatment in Japanese Patients - GuruFocus.com (NASDAQ:ENTA)
www.gurufocus.com - January 13 at 3:56 PM
News IconEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Projected to Achieve ... - Stock Observer (NASDAQ:ENTA)
www.thestockobserver.com - January 12 at 3:37 AM
finance.yahoo.com logoEntana Pharmaceuticals Releases Study Results of Hepatitis Treatment in Japanese Patients (NASDAQ:ENTA)
finance.yahoo.com - January 11 at 5:33 PM
tmcnet.com logoEnanta Announces High SVR12 Rates Achieved in Genotype … (NASDAQ:ENTA)
www.tmcnet.com - January 9 at 5:48 PM
finance.yahoo.com logoEight Weeks of Treatment with AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen of Glecaprevir/Pibrentasvir (G/P) for Chronic Hepatitis C Achieved High SVR Rates in Genotype 1 Japanese Patients (NASDAQ:ENTA)
finance.yahoo.com - January 9 at 5:48 PM
finance.yahoo.com logoEnanta Announces High SVR12 Rates Achieved in Genotype 1 Chronic HCV Infected Japanese Patients with Eight Weeks of Treatment with AbbVie’s Investigational, Pan-Genotypic, Ribavirin-free Regimen of Glecaprevir/Pibrentasvir (G/P) (NASDAQ:ENTA)
finance.yahoo.com - January 9 at 5:48 PM
streetinsider.com logoEnanta Pharma (ENTA) Provides Update on Business, R&D Ahead of JPMorgan Conference (NASDAQ:ENTA)
www.streetinsider.com - January 7 at 4:34 AM
investornewswire.com logoEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Records An Impact Score Of 83 - Investor Newswire (NASDAQ:ENTA)
www.investornewswire.com - January 6 at 5:34 PM
streetinsider.com logoEnanta Pharma (ENTA) Provides Update on Business, R&D Ahead ... - StreetInsider.com (NASDAQ:ENTA)
www.streetinsider.com - January 6 at 5:34 PM
finance.yahoo.com logo8:09 am Enanta Pharmaceuticals announces highlights of its business overview and research and development program update that will be presented at the 35th Annual J.P. Morgan Healthcare Conference on January 11 at 9:00am PT (NASDAQ:ENTA)
finance.yahoo.com - January 6 at 5:34 PM
biz.yahoo.com logoENANTA PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:ENTA)
biz.yahoo.com - January 6 at 5:34 PM
publicnow.com logoEnanta Pharmaceuticals Announces Highlights of Business Overview and Update on its Research and Development Programs to be Presented at the 35th Annual J.P. Morgan Healthcare Conference (NASDAQ:ENTA)
www.publicnow.com - January 6 at 5:34 PM
News IconFDA Grants Fast Track Designation to Enanta’s EDP-305, for the treatment of NASH with Liver Fibrosis (NASDAQ:ENTA)
hepatitiscnewdrugs.blogspot.com - January 5 at 10:50 PM

Social

What is Enanta Pharmaceuticals' stock symbol?

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

Where is Enanta Pharmaceuticals' stock going? Where will Enanta Pharmaceuticals' stock price be in 2017?

3 analysts have issued twelve-month price objectives for Enanta Pharmaceuticals' shares. Their predictions range from $26.00 to $27.00. On average, they anticipate Enanta Pharmaceuticals' stock price to reach $26.50 in the next year.

When will Enanta Pharmaceuticals announce their earnings?

Enanta Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, May, 8th 2017.

What are analysts saying about Enanta Pharmaceuticals stock?

Here are some recent quotes from research analysts about Enanta Pharmaceuticals stock:

  • According to Zacks Investment Research, "Enanta Pharmaceuticals, Inc. is a biotechnology company. It engages in the research and development of molecule drugs for the treatment of infectious diseases such as hepatitis C virus, respiratory tract infections, intravenous and oral treatments. Enanta Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts. " (11/29/2016)

  • J P Morgan Chase & Co analysts commented, "Today after market close, Enanta reported F3Q financial results and provided a pipeline update. While we expect AbbVie’s Viekira Pak to remain a key driver for ENTA shares in 2016, we see the company’s wholly owned assets becoming increasingly important valuation drivers over time." (8/9/2016)

Who owns Enanta Pharmaceuticals stock?

Enanta Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (3.02%), State Street Corp (2.98%), FMR LLC (2.06%), Stonepine Capital Management LLC (1.22%), Armistice Capital LLC (1.20%) and Dimensional Fund Advisors LP (0.94%). Company insiders that own Enanta Pharmaceuticals stock include Jay R Luly, Nathaniel S Gardiner, Paul J Mellett, Terry Vance and Yat Sun Or.

Who sold Enanta Pharmaceuticals stock? Who is selling Enanta Pharmaceuticals stock?

Enanta Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Mcclain Value Management LLC, Numeric Investors LLC, FMR LLC, GSA Capital Partners LLP and Envestnet Asset Management Inc..

Who bought Enanta Pharmaceuticals stock? Who is buying Enanta Pharmaceuticals stock?

Enanta Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Stonepine Capital Management LLC, Dimensional Fund Advisors LP, Opaleye Management Inc., Russell Investments Group Ltd., Guggenheim Capital LLC, Two Sigma Investments LP and Armistice Capital LLC. Company insiders that have bought Enanta Pharmaceuticals stock in the last two years include Nathaniel S Gardiner and Terry Vance.

How do I buy Enanta Pharmaceuticals stock?

Shares of Enanta Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Enanta Pharmaceuticals stock cost?

One share of Enanta Pharmaceuticals stock can currently be purchased for approximately $27.72.

Enanta Pharmaceuticals (NASDAQ:ENTA) Chart for Monday, February, 27, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Enanta Pharmaceuticals (NASDAQ:ENTA)

Earnings History Chart

Earnings by Quarter for Enanta Pharmaceuticals (NASDAQ:ENTA)

Dividend History Chart

Dividend Payments by Quarter for Enanta Pharmaceuticals (NASDAQ:ENTA)

Last Updated on 2/27/2017 by MarketBeat.com Staff